Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H. Fontaine C, et al. Among authors: awada a. Breast Cancer Res Treat. 2019 Aug;176(3):607-615. doi: 10.1007/s10549-019-05259-z. Epub 2019 May 8. Breast Cancer Res Treat. 2019. PMID: 31069589 Clinical Trial.
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R. Piccart MJ, et al. Among authors: awada a. Ann Oncol. 1995 Sep;6(7):673-7. doi: 10.1093/oxfordjournals.annonc.a059283. Ann Oncol. 1995. PMID: 8664188 Free article. Clinical Trial.
Molecular profiling of a tumor of unknown origin.
Ismael G, de Azambuja E, Awada A. Ismael G, et al. Among authors: awada a. N Engl J Med. 2006 Sep 7;355(10):1071-2. doi: 10.1056/NEJMc061533. N Engl J Med. 2006. PMID: 16957161 No abstract available.
Molecular targeted therapies in breast cancer: where are we now?
Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Widakowich C, et al. Among authors: awada a. Int J Biochem Cell Biol. 2007;39(7-8):1375-87. doi: 10.1016/j.biocel.2007.04.015. Epub 2007 May 4. Int J Biochem Cell Biol. 2007. PMID: 17543572 Review.
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I. Neven P, et al. Among authors: awada a. Breast Cancer Res Treat. 2008 May;109(1):59-65. doi: 10.1007/s10549-007-9628-2. Epub 2007 Jun 26. Breast Cancer Res Treat. 2008. PMID: 17592772 Free article. Clinical Trial.
Novel cytotoxic drugs: old challenges, new solutions.
Ismael GF, Rosa DD, Mano MS, Awada A. Ismael GF, et al. Among authors: awada a. Cancer Treat Rev. 2008 Feb;34(1):81-91. doi: 10.1016/j.ctrv.2007.08.001. Epub 2007 Oct 1. Cancer Treat Rev. 2008. PMID: 17905518 Review.
557 results